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Abstract. Plasmodium vivax causes debilitating but usually non-lethal malaria in most of Asia and South America.
Prevention of relapse after otherwise effective therapy for the acute attack requires a standard daily dose of primaquine
administered over 14 days. This regimen has < 90% efficacy in Thailand, and is widely regarded as ineffective because
of poor compliance over the relatively long duration of dosing. We evaluated the efficacy, safety, and tolerability of
alternative primaquine dosing regimens combined with artesunate among 399 Thai patients with acute, symptomatic
P. vivax malaria. Patients were randomly assigned to one of six treatment groups: all patients received artesunate, 100
mg once a day for 5 days. Groups 1–5 then received primaquine, 30 mg a day for 5, 7, 9, 11, and 14 days, respectively.
Group 6 received primaquine, 30 mg twice a day for 7 days. The 28-day cure rates were 85%, 89%, 94%, 100%, and 96%,
respectively. Treatment of P. vivax malaria with artesunate for 5 days followed by high-dose primaquine, 30 mg twice
a day for 7 days, was highly effective, well-tolerated, and equivalent or superior to the standard regimen of primaquine
therapy.
INTRODUCTION
Plasmodium vivax, the predominant species of malaria
parasite, has a relapse mechanism that results in the reappear-
ance of parasitemia arising from the pre-erythrocytic hepatic-
stage hypnozoite.1 This parasite affects millions of persons
living in tropical areas and is an important cause of morbidity
in Central and South America and Asia.2 In Thailand, the
current standard treatment for P. vivax malaria is chloro-
quine, 1,500 mg over 3 days, followed by primaquine, 15 mg a
day for 14 days. The acute phase of a P. vivax infection has
been successfully treated with chloroquine in Thailand3 but
not in eastern Indonesia.4 Many studies in Thailand have
demonstrated that the standard regimen of primaquine
showed relatively high relapse rates.3–6 Because higher doses
of primaquine showed good efficacy against relapse in Thai-
land,7–9 the observed poor efficacy of the standard regimen is
often attributed to an intrinsic tolerance of primaquine by
parasites in the region,4,10,11 such as the well-known tolerance of
the Chesson strain of P. vivax from New Guinea.12
Primaquine, an 8-aminoquinoline, has been the drug of
choice for radical cure of P. vivax malaria since 1950. Al-
though therapeutic application of primaquine is restricted be-
cause of its reported adverse events,13–17 it is the only drug
currently available to prevent relapse of P. vivax malaria.
Numerous studies have shown relatively poor efficacy against
relapse without supervision of compliance to the 14-day regi-
men. The regimen is widely viewed as impractical among ma-
laria control officers. In light of the remarkably good safety
and tolerability of a 30-mg regimen given for prophylaxis
against malaria over prolonged periods,7,18 some workers sug-
gested abbreviated, higher-dose regimens of primaquine may
improve the effectiveness of primaquine against relapse.19
Artesunate, a sodium salt of the hemisuccinate ester of
artemisinin, has proven efficacious for treatment of blood
stage P. vivax malaria.7,17,18 Because chloroquine-resistant
P. vivax malaria continues to develop and mixed infections
with P. falciparum and P. vivax are not uncommon, especially
in Southeast Asia,8,20,21 artesunate may be a possible alter-
native treatment for acute P. vivax malaria in the future. This
strategy, a single treatment for P. falciparum and P. vivax ma-
laria, avoids risks to patients that hinge upon correct species
diagnosis, i.e., receiving ineffective chloroquine therapy for a
dangerous drug-resistant infection with P. falciparum diagnosed
as P. vivax malaria.
The use of artesunate in the studies reported here offered
the important advantage of avoiding the confounding effects
of a drug such as chloroquine with its relatively long plasma
half-life.22–24 Lingering chloroquine in the blood suppresses
relapse after ineffective primaquine therapy.25 The rapid ex-
cretion of artesunate enabled us to assess the efficacy of pri-
maquine against relapse within 28 days.26 The objectives of
this study were to determine the efficacy, safety, and toler-
ability of artesunate with selected regimens of primaquine
and the parasite and fever clearance times.
PATIENTS AND METHODS
The study was reviewed and approved by the Ethics Com-
mittee of the Faculty of Tropical Medicine, Mahidol Univer-
sity (Bangkok, Thailand). Before enrollment in the study,
written informed consent was obtained from all patients. The
study was a randomized, open-label, prospective study. Pa-
tients admitted to the Bangkok Hospital for Tropical Dis-
eases were recruited if they were slide-positive for P. vivax,
12–60 years of age, weighed more than 30 kg, and agreed to
remain in the hospital for 28 days. Reasons for exclusion
included pregnancy, history of antimalarial drug treatment
within the preceding two weeks, mixed P. vivax and P. falci-
parum infections, unwillingness to remain hospitalized for 28
days, and a glucose-6-phosphate dehydrogenase (G6PD) de-
ficiency.
All patients received artesunate, 600 mg over 5 days and
were then randomly assigned into 1 of 6 groups. Groups 1–5
received 30 mg of primaquine daily over durations of 5, 7, 9,
11, and 14 days, respectively. Group 6 received primaquine,
30 mg twice a day (60 mg a day) for 7 days.
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Laboratory tests included a complete blood count and
blood chemistry (liver and renal function tests), and urinalysis
was performed prior to treatment and repeated weekly until
patients were discharged. Hematologic tests were performed
using ADVIA 120 (Bayer, Leverkusen, Germany) and the
biochemistry tests were performed using INTEGRA 400
(Roche, Basel, Switzerland). A qualitative test of G6PD ac-
tivity was performed using a rapid fluorescent spot (Beutler)
test.27–29 Thick and thin blood films were obtained from fin-
ger pricks and stained with Giemsa. Blood smears were ex-
amined every 12 hours from initiation of treatment until they
were negative on two consecutive occasions; thereafter blood
smears were examined daily until patients were discharged.
Blood films were considered negative if no parasites were
seen in 200 oil-immersion fields on a thick blood film. Para-
sitemias (asexual parasite/microliter of blood) were deter-
mined by counting the number per 200 leukocytes (thick film)
or the number per 1,000 erythrocytes (thin film). Parasite
clearance time was expressed in hours from the start of treat-
ment until the parasite counts decreased below the level of
detection for at least 24 hours.
Vital signs except blood pressure were measured every four
hours. Blood pressure was measured daily. Monitoring of
signs and symptoms of malaria and adverse events was per-
formed daily for the first seven days of admission and weekly
thereafter. All patients were closely monitored for the clinical
signs of intravascular hemolysis and hemoglobinuria. Fever
clearance time was defined as the time from the start of treat-
ment until the oral temperature decreased below 37.5°C for at
least 48 hours.
Patients with reappearance of parasitemia after treatment
with any of the six regimens were treated with chloroquine
(30 mg/kg) and primaquine (15 mg once a day for 14 days) as
a standard treatment of the hospital. The patients with sub-
sequent appearance of a sexual form of P. falciparum were
treated with artesunate (600 mg) followed by mefloquine (25
mg/kg). Patients having recurrent parasitemia on or before
day 14 were considered artesunate treatment failures, whereas
recurrent parasitemia between days 15 and 28 were considered
primaquine treatment failures. All patients with concurrent P.
falciparum malaria were considered failures to treatment, ex-
cluded from the study, and not included in the analysis of the
cure rate at 28 days.
The clinical efficacies among groups were estimated by
comparing relapse rates observed after 28-day follow-up of
patients in each groups. Descriptive statistics and statistical
analysis were conducted using the Epi Info version 6.04 (USD
Inc., Stone Mountain, GA) software package. All statistical
tests were two-tailed and a significance level of 0.05 was used.
RESULTS
Three hundred ninety-nine patients with acute symptom-
atic P. vivax malaria infection were recruited into the study.
The baseline demographic, clinical, and pre-treatment char-
acteristic data were comparable (Table 1). Most patients re-
ported recent travel to the Thailand-Myanmar border, where
they presumably acquired their infections. There is no risk of
malaria in Bangkok, and risk is low in most other areas of
Thailand.
During the follow-up period, 77 patients left the hospital
before completing 28 days of follow up (8 in group 1, 12 in
group 2, 10 in group 3, 16 in group 4, 14 in group 5, and 17 in
group 6) for personal reasons unrelated to side effects of
treatment. All patients who left the hospital were asymptom-
atic and without parasitemia before being discharged. None
of the patients who left the study before day 28 developed
P. falciparum malaria. Fever and parasitemia disappeared in
all patients within 48 hours (Table 2). No recurrence of par-
asitemia occurred before day 15; thus, all recurrences were
classified as primaquine treatment failures. Almost all recur-
TABLE 1
Baseline clinical and laboratory characteristics of patients in the study*
Characteristic
Group 1
(n  68)
Group 2
(n  69)
Group 3
(n  66)
Group 4
(n  64)
Group 5
(n  66)
Group 6
(n  66)
Sex (M:F) 42:26 46:24 46:19 44:21 41:21 37:29
Mean (SD) age, years 26.2 (9.4) 24.5 (8.1) 22.9 (5.8) 23.7 (8.1) 24.1 (8.2) 23.7 (7.2)
Mean (SD) height, cm 160.6 (8.4) 159.2 (7.2) 161.2 (7.1) 160.4 (7.1) 159.8 (6.6) 159.0 (7.6)
Mean (SD) weight, kg 53.6 (7.7) 53.3 (7.9) 53.0 (7.9) 52.8 (8.5) 52.8 (8.2) 51.2 (7.2)
Fever, mean (SD)
Duration of fever before
admission, days
4.8 (3.6) 4.2 (1.8) 5.1 (4.7) 5.2 (5.1) 4.9 (3.1) 4.8 (3.1)
Highest temperature, °C 37.8 (1.0) 38.0 (1.2) 38.0 (1.0) 37.8 (0.9) 37.7 (0.8) 37.9 (1.0)
No. of patients with
Splenomegaly 0 2 1 1 3 3
Hepatomegaly 21 11 17 10 13 9
First malaria attack 37 28 32 28 38 37
Geometric mean parasitemia
(range)/L
6,410 (75–65,520) 6,016 (63–48,500) 5,993 (42–88,480) 5,192 (22–41,680) 5,616 (49–54,120) 6,323 (105–54,120)
Laboratory results, mean (SD)
Hematocrit, % 37.2 (5.6) 35.6 (5.9) 37.0 (6.4) 37.6 (5.9) 36.2 (5.6) 36.5 (6.2)
White blood cell count/L 5.5 (1.6) 5.5 (1.7) 6.3 (2.1) 6.6 (2.1) 6.1 (1.8) 5.6 (1.5)
Blood urea nitrogen, mg/dL 14.9 (4.2) 15.7 (4.6) 14.4 (4.9) 14.8 (4.4) 15.4 (7.1) 14.6 (4.9)
Serum creatinine, mg/dL 0.8 (0.1) 0.8 (0.1) 0.8 (0.1) 0.8 (0.1) 0.8 (0.3) 0.8 (0.1)
Total bilirubin, mg/dL 1.5 (0.8) 1.6 (1.1) 1.7 (1.4) 1.5 (1.0) 1.5 (1.0) 1.3 (0.6)
Serum AST, U/L 34.3 (28.4) 33.9 (21.7) 39.2 (40.1) 29.5 (19.1) 31.5 (16.1) 31.0 (15.2)
Serum ALT, U/L 34.5 (48.4) 35.8 (36.0) 35.0 (37.8) 30.1 (24.0) 34.6 (35.0) 32.6 (31.4)
Alkaline phosphatase, U/L 117.4 (68.4) 120.7 (55.1) 123.9 (63.4) 122.8 (61.0) 127.2 (92.7) 126.6 (62.7)
Albumin, g/dL 3.7 (0.4) 3.7 (0.4) 3.7 (0.5) 3.8 (0.5) 3.7 (0.5) 3.7 (0.4)
* For definition of groups, see Patients and Methods. AST  aspartate aminotransferase; ALT  alanine aminotransferase.
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rences occurred after only 5, 7, or 9 days of daily primaquine
dosing with 30 mg (9 of 60 treated, 6 of 57 treated, and 2 of 56
treated, respectively). No recurrences appeared after 11 or 14
days of the same dose. Among patients given twice-a-day
primaquine dosing with 30 mg of primaquine for 7 days, 2
recurrences appeared among the 49 persons treated (Table
2).There were no changes in hematocrit levels (Figure 1). No
serious adverse events were observed, and no significant dif-
ferences in adverse events were observed among the groups
(Table 3).
DISCUSSION
Abbreviated high-dose regimens of primaquine after arte-
sunate therapy provided efficacious, safe, and well-tolerated
therapy against relapse by P. vivax acquired in Thailand. The
complete efficacy of artestunate against P. vivax malaria7 and
its short plasma half-life enabled us to evaluate the efficacy of
primaquine against early relapse by P. vivax. In studies of
patients infected by tropical Asian strains of P. vivax and not
treated with primaquine, 197 (75%) of 263 persons who re-
lapsed did so on or before day 28.24 We believe the 28-day
period of follow-up captured most possible relapses in this
study population. Regimens of 30 mg a day for 5 or 7 days
proved significantly less efficacious (< 90%) against early re-
lapse than 30 mg a day over 9, 11, or 14 days (> 90%) (P <
0.05). The regimen of 2 daily doses of 30 mg for 7 days was
94% efficacious against early relapse. Because of prolonged
use of primaquine, which can eliminate the asexual erythro-
cytic stage of P. vivax, none of the patients developed recur-
rences before day 15.
Patients given the dose of 60 mg of primaquine divided
into 2 daily doses over 7 days tolerated this drug without
serious adverse events and without substantially altered blood
or liver function profiles. Although methemoglobin levels
were not measured in this study, none of the patients devel-
oped clinical signs and symptoms of methemoglobinemia,
such as bluish discoloration of the skin. This corroborated
similar findings of good tolerability of a 60-mg daily dose
given in combination with chloroquine in the setting of a
placebo-controlled, double-blinded trial.30 We consider that
regimen a practical alternative to 30 mg of primaquine a day
over 9, 11, or 14 days among patients considered good can-
didates to receive this regimen, i.e., not pregnant and a G6PD
deficiency.
Many countries in malaria-endemic regions adopted a dose
of 15 mg of primaquine a day for 5 days as standard anti-
relapse therapy against P. vivax on the basis of findings in
poorly controlled clinical trials.12 Recent well-controlled tri-
als have shown that this regimen was almost completely in-
effective against relapse by P. vivax in Asia.31 Health officers
responsible for malaria therapy policies cite the impracticality
of a 14-day regimen as the basis of opting for the abbreviated
regimen. Our findings support the concept of adopting a 30
mg twice a day regimen for 7 days as a safe, well-tolerated,
and efficacious alternative that may prove more practical.
However, the safety of such a regimen in patients with G6PD
deficiency is doubtful and adoption of such a regimen would
FIGURE 1. Mean hematocrit level of patients receiving high-dose primaquine.
TABLE 2
Therapeutic responses of patients in the study*
Characteristic
Group 1
(n  68)
Group 2
(n  69)
Group 3
(n  66)
Group 4
(n  64)
Group 5
(n  66)
Group 6
(n  66)
No. of dropouts 8 12 10 16 14 17
No. of patients who completed follow-up 60 57 56 48 52 49
Cure rate at day 28 (%) 51 (85) 51 (89) 54 (94) 48 (100) 52 (100) 47 (96)
Relapse rate at day 28 (%) 9 (15) 6 (11) 2 (4) 0 0 2 (4)
Day of appearance 19, 20, 22, 23, 25, 28 20, 21, 23, 24, 28 14, 21 NA NA 22, 23
Mean (SD) fever clearance time, hr 16.8 (14.4) 20.0 (21.6) 14.5 (9.3) 13.8 (11.4) 19.6 (22.2) 21.4 (23.5)
Mean (SD) parasite clearance time, hr 34.9 (8.4) 36.0 (10.5) 35.7 (10.1) 34.2 (9.9) 37.2 (11.4) 36.8 (10.4)
* NA  not available. Group 1  group 4 and group 5 (P  0.004 and 0.003). Group 2  group 4 and group 5 (P  0.015 and 0.014).
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depend upon availability of reliable G6PD testing prior to
drug administration.
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